IFNAR1 — Interferon Alpha Receptor 1

IFNAR1 — Interferon Alpha Receptor 1

Overview

IFNAR1 (Interferon Alpha Receptor 1) encodes the alpha subunit of the type I interferon receptor, a critical component of the antiviral and immunomodulatory signaling pathway that has increasingly been implicated in neurodegenerative disease pathogenesis. Type I interferons (IFN-α, IFN-β, IFN-ω, IFN-κ) are cytokines that mediate innate antiviral immunity and modulate adaptive immune responses. In the central nervous system, IFNAR1 signaling influences microglial activation, astrocyte reactivity, neuronal survival, and neuroinflammation, making it a key player in the molecular interface between immune signaling and neurodegeneration in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), and related disorders [1](https://pubmed.ncbi.nlm.nih.gov/21743993/).

IFNAR1 — Interferon Alpha Receptor 1

Overview

IFNAR1 (Interferon Alpha Receptor 1) encodes the alpha subunit of the type I interferon receptor, a critical component of the antiviral and immunomodulatory signaling pathway that has increasingly been implicated in neurodegenerative disease pathogenesis. Type I interferons (IFN-α, IFN-β, IFN-ω, IFN-κ) are cytokines that mediate innate antiviral immunity and modulate adaptive immune responses. In the central nervous system, IFNAR1 signaling influences microglial activation, astrocyte reactivity, neuronal survival, and neuroinflammation, making it a key player in the molecular interface between immune signaling and neurodegeneration in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), and related disorders [1](https://pubmed.ncbi.nlm.nih.gov/21743993/).

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IFNAR1 — Interferon Alpha Receptor 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>IFNAR1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Interferon Alpha and Beta Receptor Subunit 1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>21q22.11</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/3454" target="_blank">3454</a></td></tr>
<tr><td><strong>Ensembl ID</strong></td><td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142149" target="_blank">ENSG00000142149</a></td></tr>
<tr><td><strong>OMIM</strong></td><td>146590</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P17181" target="_blank">P17181</a></td></tr>
<tr><td><strong>Protein Class</strong></td><td>Type I Cytokine Receptor</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Ubiquitous (immune cells, [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), [microglia](/cell-types/microglia-neuroinflammation))</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), Aicardi-Goutières Syndrome, SARS-CoV-2 Neurotropism</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The IFNAR1 gene is located on chromosome 21q22.11, a region of significance for Down syndrome (trisomy 21), where increased gene dosage may contribute to altered interferon responses. The gene spans approximately 30 kb and consists of 22 exons encoding a 557-amino acid type I transmembrane protein [2](https://pubmed.ncbi.nlm.nih.gov/23401003/). The promoter region contains multiple regulatory elements including ISRE (Interferon-Stimulated Response Element) sites, allowing interferon-dependent transcriptional regulation.

Protein Domain Structure

IFNAR1 has a distinctive receptor architecture:

Receptor Complex

The functional type I interferon receptor is a heterodimer:

• IFNAR1: Ligand-binding chain with lower affinity
• IFNAR2: Co-receptor with higher affinity for type I IFNs
• Both subunits required for full signal transduction

Expression Patterns

Cellular Distribution

| Cell Type | Expression Level | Functional Significance |
|-----------|------------------|-------------------------|
| [Microglia](/cell-types/microglia-neuroinflammation) | High | Primary interferon-responsive CNS cell |
| [Astrocytes](/entities/astrocytes) | Moderate | Modulates neuroinflammatory responses |
| [Neurons](/entities/neurons) | Low-Moderate | Direct interferon effects on neuronal function |
| Oligodendrocytes | Low | Potential myelin modulation |
| T-lymphocytes | High | Peripheral immune signaling |
| Monocytes/Macrophages | High | Innate immune activation |
| Dendritic Cells | High | Antigen presentation |

Brain Region Distribution

• Cortex: Moderate expression, particularly in layer neurons
• Hippocampus: Higher expression in CA1/CA3 regions
• Substantia nigra: Moderate expression in dopaminergic neurons
• Cerebellum: Lower expression in Purkinje cells

Regulation

IFNAR1 expression is dynamically regulated:

• Upregulated by: IFN-α/β, TNF-α, LPS, viral infections
• Downregulated by: Glucocorticoids, anti-inflammatory cytokines
• Activity-dependent: Neuronal activity can modulate expression

Molecular Mechanisms

JAK-STAT Signaling Pathway

Type I interferon signaling through IFNAR1 activates the JAK-STAT cascade:

Downstream Effectors

Key interferon-stimulated genes (ISGs) include:

• MX1/MxA: Viral inhibition
• OAS/RNase L: Viral RNA degradation
• PKR: Protein kinase R, translation inhibition
• IFITM: Interferon-induced transmembrane proteins
• HLA genes: MHC class I antigen presentation

Non-JAK-STAT Pathways

IFNAR1 also activates alternative signaling:

• PI3K/AKT pathway: Cell survival and metabolism
• MAPK pathway: Stress responses
• NOTCH signaling: Developmental effects
• cAMP signaling: Modulates inflammation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Type I interferon signaling is increasingly recognized in AD pathogenesis:

Chronic Neuroinflammation

• Elevated IFN-α levels in AD brain and CSF
• IFNAR1 upregulated in AD microglia and astrocytes
• Chronic type I IFN signaling drives pro-inflammatory microglial phenotype
• ISG signature detected in AD brain tissue [3](https://pubmed.ncbi.nlm.nih.gov/25363767/)

Amyloid Interaction

• Aβ oligomers can induce type I interferon production
• IFN signaling may accelerate amyloid deposition
• Microglial IFN responses reduce Aβ clearance
• Therapeutic implication: IFN blockade may reduce pathology

Tau Pathology

• Interferon signaling may influence tau phosphorylation
• Neurofibrillary tangle burden correlates with ISG expression
• IFN-induced kinases may modify tau

Therapeutic Implications

• JAK inhibitors: Tofacitinib, Baricitinib being tested in AD
• IFNAR antagonists: Blocking antibody approaches
• Anti-interferon therapies: Current clinical trials [4](https://pubmed.ncbi.nlm.nih.gov/36258475/)

Parkinson's Disease

Microglial Activation

• IFNAR1 upregulated in substantia nigra of PD brains
• Type I IFN promotes M1-like pro-inflammatory microglial phenotype
• Chronic interferon exposure contributes to dopaminergic neuron loss

Genetic Associations

• IFNAR1 R89C variant: Associated with increased PD risk
• IFNAR2 variants: Altered interferon signaling in PD
• Genes in interferon pathway show GWAS significance

Viral Links

• Post-encephalitic Parkinsonism links to viral infections
• SARS-CoV-2 may trigger parkinsonism via interferon pathways
• Influenza and HSV-1 associations with PD [5](https://pubmed.ncbi.nlm.nih.gov/30361426/)

Multiple Sclerosis

Dual Role

• Therapeutic: IFN-β treatment is established MS therapy
• Pathogenic: Excess type I IFN may drive disease

IFN-β Therapy

• Recombinant IFN-β reduces relapse rate
• May work through anti-inflammatory mechanisms
• Not effective in all patients (IFN non-responders)

Disease Mechanisms

• Type I IFN promotes antigen presentation
• Drives Th1 differentiation
• May exacerbate demyelination in some contexts [6](https://pubmed.ncbi.nlm.nih.gov/33277862/)

Aicardi-Goutières Syndrome

• Autoimmune disorder with interferon signature
• Mutations in TREX1, RNASEH2, SAMHD1, ADAR
• IFNAR1 expression elevated
• Presents with early-onset neurodegeneration

COVID-19 and Neurodegeneration

• SARS-CoV-2 can infect CNS
• Type I interferon response in brain
• Long COVID includes neurological symptoms
• Potential for accelerated neurodegeneration

Therapeutic Targeting

JAK Inhibitors

| Drug | Target | Clinical Status |
|------|--------|-----------------|
| Tofacitinib | JAK1/2/3 | Phase 2 in AD |
| Baricitinib | JAK1/2 | Phase 2 in PD |
| Ruxolitinib | JAK1/2 | Preclinical |

Interferon Antagonists

• Anti-IFNAR antibodies: Under development
• Soluble IFNAR: Decoy receptor approaches
• IFN-neutralizing proteins: Natural inhibitors

Gene Therapy Approaches

• Knockdown of IFNAR1 expression
• Modulation of JAK-STAT signaling
• Delivery of negative regulators

Signaling Cross-Talk

Genetic Variants and Polymorphisms

Disease-Associated Variants

| Variant | Effect | Disease Association |
|---------|--------|---------------------|
| R89C | Reduced signaling | PD risk |
| T341M | Altered function | MS (protective) |
| Promoter variants | Expression change | AD risk |

Population Genetics

• Common polymorphisms in IFNAR1 promoter
• May influence interferon response magnitude
• Implications for viral susceptibility and autoimmunity

Biomarker Potential

CSF Biomarkers

• IFN-α levels: Elevated in AD, MS
• ISG signatures: mRNA profiles in immune cells
• Soluble IFNAR: Potential disease marker

Imaging

• PET ligands for microglial activation
• Correlate with IFN-driven inflammation

Key Publications

See Also

• [JAK-STAT Signaling in Neurodegeneration](/mechanisms/jak-stat-signaling-neurodegeneration)
• [Neuroinflammation Overview](/mechanisms/neuroinflammation-overview)
• [Type I Interferon in CNS Disease](/mechanisms/type-interferon-cns)
• [Alzheimer's Disease Immune Dysfunction](/diseases/alzheimers-disease)
• [Parkinson's Disease Neuroinflammation](/diseases/parkinsons-disease)
• [Microglial Activation States](/cell-types/microglia-neuroinflammation)

Pathway Diagram

The following diagram shows the key molecular relationships involving IFNAR1 — Interferon Alpha Receptor 1 discovered through SciDEX knowledge graph analysis: